Coronavirus company news summary – NRx Pharmaceuticals and IIBR collaborate on Covid-19 vaccine development - Moderna enters vaccine supply agreement with Argentina
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – NRx Pharmaceuticals and IIBR collaborate on Covid-19 vaccine development – Moderna enters vaccine supply agreement with Argentina

13 Jul 2021

NRx Pharmaceuticals, a clinical stage pharmaceutical company, has signed a Memorandum of Understanding with the Government of Israel to license the exclusive global development, manufacturing, and marketing of the Covid-19 vaccine developed by the Israel Institute for Biological Research (IIBR). The BriLife vaccine is based on a previous, US Food and Drug Administration-approved vaccine platform that was further optimised by the IIBR. The vaccine is expected to be initially delivered by traditional injection.

Moderna has entered into an agreement with the government of Argentina to supply 20 million doses of Moderna’s Covid-19 vaccine or its updated variant booster vaccine, if authorised. The delivery the doses is scheduled to start in the first quarter of 2022. The company stated that it continues to be committed to making its Covid-19 vaccines available to the world as it seeks to end the pandemic through vaccination efforts.

BioNTech has announced that Fosun Industrial, a wholly owned subsidiary of its partner Shanghai Fosun Pharmaceutical, has entered into advance procurement agreements to supply its mRNA-based Covid-19 vaccine with Taiwan Semiconductor Manufacturing Co., Hon Hai, Yonglin Charity Foundation and Zuellig Pharma, respectively. Fosun Industrial will sell a total of 10 million doses of the vaccines to Zuellig Pharma. These Covid-19 mRNA vaccines will support local vaccination after being donated to the relevant agency of disease control in Taiwan.